Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Velimogene aliplasmid

Drug Profile

Velimogene aliplasmid

Alternative Names: Allovectin; Allovectin-7; VCL-1005; VCL-1005-208

Latest Information Update: 13 Aug 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vical
  • Class Antineoplastics; DNA; Gene therapies; Lipids
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Head and neck cancer; Lymphoma; Malignant melanoma; Orofacial cancer; Renal cancer

Most Recent Events

  • 12 Aug 2013 Discontinued - Phase-III for Malignant melanoma in Belgium (Intratumoural)
  • 12 Aug 2013 Discontinued - Phase-III for Malignant melanoma in Brazil (Intratumoural)
  • 12 Aug 2013 Discontinued - Phase-III for Malignant melanoma in Canada (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top